Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–11 of 11 trials
Active filters
Clinical trials found
Published and searchable clinical trials
NCT06712810
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
NCT02332980
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +48 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
NCT04578600
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +39 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
NCT00723099
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
- Locations
-
- University of Colorado Hospital Aurora, Colorado, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
NCT01076543
- Conditions
- AIDS-Related Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +27 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Decatur Memorial Hospital Decatur, Illinois, United States
- Ingalls Memorial Hospital Harvey, Illinois, United States
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT03277729
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NCT02153580
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, Burkitt Lymphoma, +43 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03015896
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States